NCT04116164
Safety and Targeting of Anti-hk2 Antibody in mCRPC No drug interventions other 0 terminated NCT02628379
Outcomes of FoundationOne Directed Therapy in Cancer of Unknown Primary No drug interventions Not Available Not Available completed NCT00532454
Evaluation of the Association Between CYP2D6 Genetic Polymorphisms and the Treatment Effect of Tamoxifen treatment 2 terminated NCT03632005
Negative Pressure Wound Therapy vs. Sterile Dressing for Patients Undergoing Thoracolumbar Spine Surgery No drug interventions prevention Not Available unknown_status NCT05188911
Analysis of Next Generation PET and Liquid Biopsy to Monitor mCRPC Treated With Abiraterone: ANGELA Trial Not Available Not Available unknown_status NCT04595032
MAnagement of METastatic Disease In Campania (MAMETIC) No drug interventions Not Available Not Available completed NCT02795819
Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer treatment 1 terminated NCT04492735
The Use of Indocyanine Green as a Diagnostic Adjunct for Pediatric Solid Malignancies No drug interventions Not Available Not Available recruiting NCT01875380
Regorafenib in Frail and/or Unfit for Chemotherapy Patients With Metastatic Colorectal Cancer treatment 2 completed NCT00480389
Pre-operative Administration of Sorafenib in Patients With Metastatic Renal Cell Carcinoma Undergoing Kidney Removal treatment 2 completed NCT02856867
Nintedanib Plus mFOLFOX6 for Previously Untreated Metastatic Esophagogastric Adenocarcinoma (MEGAN) treatment 2 withdrawn NCT00609401
Study Comparing Association Between Sorafenib and Interleukin-2 (IL-2) Versus Sorafenib in 1st Line Therapy in Advanced (Adv) Renal Cell Carcinoma (RCC) treatment 2 completed NCT06424210
The Role of Surgery for Esophageal Cancer With Metastatic Disease (M1) No drug interventions Not Available Not Available completed NCT01703910
Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic treatment 2 completed NCT03705403
IMMUNOtherapy and Stereotactic ABlative Radiotherapy (IMMUNOSABR) a Phase II Study treatment 2 active_not_recruiting NCT02175654
Regorafenib as Single Agent in Patients With Metastatic Colorectal Cancer (mCRC) With Any RAS or BRAF Mutation Previously Treated With FOLFOXIRI Plus Bevacizumab treatment 2 terminated NCT01855477
CPCT-02 Biopsy Protocol No drug interventions other Not Available completed NCT01020305
Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer treatment 1 / 2 terminated NCT01679405
BIBW 2992 as add-on to Gem/Cis in Advanced Biliary Tract Cancer treatment 1 terminated NCT01450683
Study of Itraconazole in Castrate-resistant Prostate Cancer (CRPC) Post-chemotherapy treatment 2 terminated NCT05789771
Abemaciclib for the Treatment of Luminal Metastatic breAst caNcer in the Real-life Clinical pracTice in Russia. Not Available Not Available completed NCT00369785
Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors supportive_care 3 completed NCT02496832
A Study of Hypoxia Imaging in Advanced Pancreatic Cancer Patients Being Treated With Gemcitabine and TH-302 or TH-302 Placebo diagnostic Not Available withdrawn NCT00406900
Melanoma Inhibitory Activity (MIA): A Serological Marker for Metastatic Uveal Melanoma No drug interventions Not Available Not Available unknown_status NCT01763970
Stereotactic Radiation Therapy for Pediatric Sarcomas No drug interventions treatment Not Available completed NCT01904916
CPCT-05 Biopsy Protocol Patient Selection No drug interventions other Not Available terminated NCT00678158
Study Using High-Dose Single Fraction Image-Guided Radiotherapy for Metastatic Lesions to Soft Tissue Masses, Lymph Node, or Bone No drug interventions treatment 1 completed NCT01484860
Study of AUY922 in Metastatic Pancreatic Cancer Who Are Resistant to First Line Chemotherapy treatment 2 terminated NCT03823989
Intravenously Administered Liposomal PROMITIL in Combination With External Beam Radiotherapy in Cancer Patients treatment 1 completed NCT01089595
Trial of Tasigna (Nilotinib) 400 mg Twice Daily Alone or With Gleevec (Imatinib Mesylate) 400 mg Daily for Patients With Advanced Gastrointestinal Stromal Tumor (GIST) treatment 2 terminated NCT01861938
Modified Melanoma Vaccine for High Risk or Low Residual Disease Patients No drug interventions treatment 2 / 3 unknown_status